Outcomes of Kidney Transplant Recipients on Dual Antiplatelet Therapy
Journal: Austin Journal of Nephrology and Hypertension (Vol.2, No. 3)Publication Date: 2015-04-15
Authors : Paul D Bailey; Hirra Ali; Michelle Lubetzky; Liise K Kayler;
Page : 1-4
Keywords : Bleeding; Renal Transplant; Antiplatelet; Plavix®; Aspirin; Complication; Kidney transplantation; Blood transfusion; Anticoagulation;
Abstract
Background: Kidney Transplant (KTX) recipients often have co morbidities requiring anti-platelet therapy with 1 or 2 agents. Whereas a few reports have examined outcomes with one agent, none have evaluated outcomes of KTX recipients on dual antiplatelet agents. Methods: Consecutive adult kidney-only recipients from 10/11-9/14 taking aspirin alone (ASA, n=135), ASA and Plavix® (DUAL, n=23), or no Antiplatelet therapy (NONE, n=209) at the time of transplantation were assessed for several outcomes post-transplantation. Results: Of 367 patients, the overall incidence of blood transfusion within 5 days of KTX was 34.6%. Compared to the NONE group, DUAL or ASA alone, were associated with perioperative blood transfusion (27.8%, 52.2%, 42.2%, p<0.01), but not reoperation for bleeding (1.0%, 0.0%, 1.5% p=0.79), delayed graft function (47.9%, 52.2%, 51.1% p=0.81), length of stay > 6 days (31.1%, 34.8%, 36.3% p=0.60), 30-day readmission (26.8%, 21.7%, 33.6% p=0.30), or overall graft failure (7.7%, 4.4%, 7.4% p=0.85), respectively. Despite univariate association, blood transfusion was not significantly associated with ASA (aOR: 1.42, CI: 0.86-2.34), or DUAL (aOR: 1.87, CI: 0.75-4.66) on multivariate analysis. Conclusion: KTX with single or dual antiplatelet therapy may not carry an increased risk of blood transfusion or other adverse outcomes after other risk factors are accounted for.
Other Latest Articles
Last modified: 2017-06-22 18:17:45